Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

Rare Disease Medications: Incentives and Regulations in the European Union

Ajay Shekhare[1], Girish kashid[2], Ajit Gayake[1], Yuvraj Mahajan[1], Krushna Agnihotri[1].

[1] Department of Regulatory Affairs, Sanjivani College of Pharmaceutical Education and Research, Kopargaon, Maharashtra, India-423601.

[2] Department of Pharmaceutical chemistry, Sanjivani College of Pharmaceutical Education and Research, Kopargaon, Maharashtra, India-423601.

(Received: 27 October 2023 Revised: 22 November Accepted: 26 December)

KEYWORDS

Orphan Drugs, Regulatory Landscape, Rare Disease Drug Development, Market Access Challenges.

ABSTRACT:

This comprehensive review explores the intricate regulatory framework surrounding orphan drugs in the European Union, emphasizing the challenges and strategic considerations for pharmaceutical companies. From obtaining orphan designation to addressing pre-clinical development challenges and navigating payer requirements, the article delves into the complexities of rare disease drug development. The conclusion highlights the imperative for collaborative efforts in overcoming these challenges to facilitate successful market access for orphan drugs in the European Union.

1. Introduction

Uncommon diseases present significant challenges to healthcare systems, affecting up to an estimated 30 million people within the European Union (EU) [1]. To address the unique needs of patients with rare conditions, Regulation No. 141/2000 was founded by the legislative bodies comprising the European Parliament and Council. This regulation along with its subsequent stipulations, seeks to encourage the advancement of pharmaceuticals targeting uncommon ailments. This is achieved through the provision of incentives, including reduced fees for regulatory processes, protocol assistance, and exclusive market rights [2][3].Central to this regulatory framework is the concept of orphan designation (OD), where For a medicinal product to qualify for incentives, approval of orphan status by the European Commission (EC) is essential. The Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) issues a favourable opinion on orphan drug status allowing access to a range of incentives, including 10 years of market exclusivity upon marketing authorization (MA) [7][8]. For a therapeutic item to meet the criteria for orphan designation, it must satisfy three primary criteria: (i) the occurrence of targeted condition within the EU should not exceed 5 in 10,000, or in the absence of incentives, the product wouldn't yield a satisfactory profitability; (ii) the item must address a condition that is life-threatening or persistently incapacitating (iii) there should be no existing effective therapy prevention, or diagnostic methods for the ailment, or the product must provide a substantial benefit to those affected. [2].The concept of 'significant benefit' was first introduced through Regulation 141/2000 and pertains to a clinically significant benefit or a substantial enhancement to patient well-being. Initially envisioned as 'clinical superiority,' it evolved to SB to address challenges in establishing superiority during early development stages. This criterion ensures that designated orphan medicinal products (OMPs) provide meaningful advancements in addressing rare diseases [4].Our comprehensive review delves into the legislative landscape, access issues, and regulatory strategies surrounding orphan drugs in the EU. By analysing 15 years of experience, we explore the complexities and nuances of demonstrating the significant benefit of Medications designated as orphan drugs within the European context [5]. The European Union has long recognized unique healthcare needs of patients with rare conditions, as exemplified as per the provisions outlined in Regulation (EC) No 141/2000 concerning orphan medicinal products (OMPs). Emphasizing equal treatment for patients with rare

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

diseases, this regulation laid the foundation for additional incentives to spur OMP development, underscoring the importance of ensuring parity in healthcare quality [6]. Existing literature highlights the substantial variability in OMP access across European countries, with diverse methodologies and indicators used in various studies. Notably, challenges in OMP uptake, specifically pertaining to Decisions regarding pricing and reimbursement (P&R) are determined at the countrywide level underscore the complexities of ensuring widespread availability [7]

Principles for rare disease drug development

Principle 1- Navigating the Regulatory Framework for Uncommon Ailments: The Involvement of Orphan Medicinal Products and Expert Engagement.

Uncommon medical conditions, characterized by a prevalence of ≤5 in 10,000 people, pose challenges due to limited understanding, complexity, and incomplete information [9]. The Regulation for European Orphan Medicinal Products (OMPs) characterizes rare diseases as conditions that are either life-threatening or chronically debilitating [10]. OMPs address these challenges, yet their benefit assessment demands specific expertise [11]. The creation of the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency enables the engagement of experts in regulatory determinations [12]. The OMP Regulation outlines criteria for OMP designation, Mandating a significant clinical benefit or substantial contribution to patient well-being. [13] [14]. Manufacturers must demonstrate a significant benefit, bridging the gap in existing treatments [15].National reimbursement mechanisms should align with COMP assessments, acknowledging the clinical advantage determined through OMP designation [16][17]. Germany's pricing and reimbursement rules embody this principle, assuming "innovativeness" and added medical benefit based on COMP assessments [18].In conclusion, expert involvement is pivotal in navigating the complexities of rare diseases and ensuring fair access to precise information and top-notch healthcare for patients.

Principle 2 - Integrating Disease-Specific Expertise for Informed Evaluation In the realm of rare diseases, the utilization of Orphan Medicinal Products.

National authorities must incorporate disease-specific expertise into the value assessment of orphan medicinal products (OMPs), reflecting the complexity and limited data in rare diseases [17]. Due to the scarcity of robust observational data, qualitative insights from healthcare professionals (HCPs) and patients are crucial for a comprehensive evaluation [18]. Patient involvement, recognized in clinical trial design and regulatory decisions, becomes especially vital in rare diseases [19].Patients, caregivers, and HCPs offer first and testimony on the patient experience, compensating for the lack of published data [19][20]. In rare diseases, where individuals frequently become specialists in their field conditions, their involvement ensures a more accurate portrayal of symptoms and manifestations [17]. Physicians managing rare diseases may lack exposure to a diverse range of cases, necessitating patient expertise. At the national level, involving rare disease experts in standing committees is essential, especially when representatives lack direct experience with a particular rare disease [17]. Collaborating with experts from reference centres within the country or consulting European/international experts for diseases without national expertise is recommended [21]. Clinical expertise, not limited to physicians, should also include nurse experts to provide a holistic view of patient care. This systematic involvement of experts aids national authorities in understanding disease contexts, reducing the risk of excluding OMPs from reimbursement without considering rare disease specificities [17]. Experts contribute valuable Data regarding disease Incidence of illness, patient impairment, and outlook on prognosis [17]

Principle 3: Rethinking Value Assessment for Orphan Medicinal Products in Rare Diseases – A Multi-Criteria Approach.

National value assessments often overlook critical aspects of rare diseases and orphan medicinal products (OMPs), impacting their accurate evaluation [22,23,25]. Conventional health result: metrics such as Quality- and Disability-Adjusted Life Years (QALY/DALY) might not sufficiently capture the gravity of the disease in these communities, Particularly because OMPs address conditions that pose a threat to life or cause significant debilitation [22,26]. Individuals affected by rare diseases frequently confront unfavourable prognoses and diminished quality of life, making standard health outcomes analysis deem clinical benefits as modest [22,26]. The complexity of evaluating OMPs is heightened by the lack of thoroughly documented alternative treatments, as comparators for benchmarking are often outdated and lack proven efficacy [23]. The

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

economic difficulties presented by medications for rare diseases, the absence of appropriate benchmarks, and the overstated incremental costs of OMPs in poorly controlled disease scenarios contribute Leading to intricate dialogues between manufacturers and regulatory bodies [22,24]. Recognizing unmet medical need as a vital element of a novel pharmaceutical product value is crucial [22,23,25].Moreover, differences in disease prevalence should be considered during assessments due to their impact on disease understanding, evidence quality, and drug pricing [27]. Although rarity might not be an inherent value element, its consideration becomes essential in evaluating alternative considerations. Approaches for evaluating multiple criteria present a chance to comprehensively integrate essential elements of orphan medicinal product (OMP) value into funding decisions. Proposed by various authors, these frameworks explicitly consider rare disease specificities [28,29,30]. Notably, The Task Force on Coordinated Access Mechanisms for Orphan Medicinal Products established by the European Commission suggested a clear value framework for OMPs employing a multi-dimensional approach [31]. This approach is also adopted Within the healthcare systems of both English and French contexts for Decisions regarding funding for treatments of rare diseases [32,33]. The effectiveness of multi-criteria assessment in evaluating OMPs resides in its organized and clear framework systematically incorporating vital elements relevant to decision-making [33,34]. It allows the formal integration of OMP-specific factors (e.g., rarity, severity, unmet need) and evaluates their added value to the healthcare system [35,36]. Additionally, these frameworks provide flexibility for considering subjective factors, including ethical concerns, patient access, the rule of rescue, and equity of opportunity.

Principle 4 -Embracing a Comprehensive Perspective – The Role of Multi-Criteria Approaches in Orphan Medicinal Product Value Assessments.

Medicinal Product (OMP) value assessments, providing a structured and transparent approach. This approach contrasts with cost-effectiveness analysis (CEA), offering a more comprehensive evaluation [37]. The European Commission's Transparent Value Framework and similar methods in English and French healthcare systems exemplify the use of multi-criteria approaches for OMPs [38,39,40]. This method allows systematic inclusion of OMP-specific factors and subjective considerations like ethical issues [41,42].

Principle 5 -Embracing Uncertainty in Orphan Medicinal Product Assessment – Tailoring Approaches for Rare Diseases.

The presence of uncertainty in evidence does not signify absence of value insufficient research for OMPs. Clinical uncertainty is inherent in most innovative medicines at approval, irrespective of patient population size. In rare diseases, quantitative uncertainty is heightened due to smaller patient populations [43]. Acceptance of uncertainty surrounding OMP value parameters should be contextualized based on disease-specific factors such as prevalence, patient heterogeneity, disease knowledge, natural history, surrogate endpoints, and comparator product efficacy [44,45]. Evaluation methods that incorporate both qualitative and quantitative aspects evaluation of medical advantage, unlike solely quantitative approaches such as Cost-Effectiveness Analysis (CEA), are more attuned to the contextual nuances of data generation [46]. Statistical uncertainty is a challenge regardless of the rare disease context of the evaluation framework, and strategies ought to be in place to prevent it from becoming a methodical rephrasing barrier to OMP access [47].

Principle 6 -Balancing Innovation and Affordability: The Impact of Regulation in Europe for Medicinal Products Addressing Rare Diseases Treatment Funding.

European Regulation for Medicinal Products Targeting Rare Diseases aimed to incentivize pharmaceutical companies to focus on rare diseases with unmet needs. However, funding for OMPs is contentious due to high per-patient costs. National health policies and pricing/reimbursement frameworks may not explicitly prioritize rare disease research [43,44].Policymakers ought to recognize the necessity to incentivize The advancement of OMPs within pricing and reimbursement frameworks Companies invest in OMPs expecting positive returns, necessitating flexibility in pricing to recoup research costs[45,46]. Restricting Compensation for specific subsets within authorized categories indications ought to be considered as a final option. While the recent surge in spending on orphan drugs results from advancements in innovation OMP expenditures (1-4% of the total pharmaceutical spending) are anticipated to remain manageable, growing to around 5% by 2020[46]. The expiration of patent protection will enable the production of generic alternatives, creating financial room for new orphan drugs [47].

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

Principle 7 -Flexible Value Framework for OMP Reimbursement: Establishing Fair Pricing Based on Added Value.

In a flexible value framework, reimbursement for Orphan Medicinal Products (OMPs) ought to be established by assessing the supplementary worth of therapy through a comprehensive process capturing pertinent aspects of rare disease features (Principle 3). Acknowledging variability in OMP values, Pricing and reimbursement structures ought to mirror this variety. To establish additional benefit, comparisons with similar OMPs, considering rarity, disease severity, and development complexity, are essential. Reimbursement can then be determined in comparison to a group of similar OMPs, allowing for a spectrum of prices within that category. Financial position should be in proportion to prices of analogous therapies and situations, not current therapies addressing the identical ailment, given that OMPs target diseases lacking adequate treatments. OMP prices should align with the prevailing cost spectrum for conditions of comparable prevalence, and the particular price should be established based on the additional value compared to those treatments, [48,49].

Principle 8 Navigating the Cost-Effectiveness Conundrum: Principles and Debates in Assessing Orphan Medicinal Products for Rare Diseases.

The use of Economic Evaluation for Efficiency in assessing Pharmaceuticals for Rare Diseases for

Uncommon Medical Conditions has sparked debate. While some advocate for a limited role, others suggest its feasibility with adjustments for OMP specificities [50-53]. Experience indicates that a framework incorporating multiple criteria may be more appropriate than a Cost-Effectiveness Analysis Tailored for Orphan Medicinal Products [54]. In Nations like France and Italy, In the context of economic evaluation supplements decisions, patient access to OMPs is relatively high [51]. When adapting a Cost-Effectiveness Analysis framework Adjustments are necessary for ICER thresholds, considering value criteria for instance, factors like the severity of the condition, existing gaps in treatment, and the prevalence of the disease [50,41,57,58]. Explicit weighting, aligned with Choices in public policy and preferences within society, is crucial to incentivize development of Orphan Medicinal Products [56-59]. Higher ICER thresholds have shown success, particularly in Uncommon Oncological Disorders, In the context of trial structures and outcome measures CEA assessment [55].

Principle 9 Navigating Limited Clinical Data: Strategies for Sustainable Establishing Pricing and Reimbursement for Orphan Medicinal Products in Products in Rare Diseases.

The sustainability of Orphan Medicinal Product (OMP) pricing and reimbursement assessments faces challenges due to the limited clinical data for rare diseases. Traditional value assessment processes rely on extensive clinical data, often difficult to obtain for rare diseases [60]. Early access programs, like France's Autorisations Temporaires d'Utilisation (ATU), address this by allowing patient access to promising treatments with mandatory data collection [61,62].Patient registries and post-authorization safety studies become essential for capturing real-world data on OMP outcomes [63]. Standardized EU-level registries, coordinated with member states, enhance data collection and adaptability [64]. Conditional reimbursement programs, tying reimbursement to real-world effectiveness, combined with registries, enable ongoing monitoring of OMP use, efficacy, and value.

Principle 10 Balancing Act: Navigating Financial Uncertainty in Orphan Medicinal Product Expenditure for Sustainable Funding in Rare Diseases.

Financial uncertainty in orphan medicinal product (OMP) expenditure is a significant concern due to challenges in predicting medicine uptake, especially in rare diseases with limited epidemiological data [65]. Elevated per-patient costs and minor fluctuations in the number of patients: Rewording lead to substantial Financial Implications variations. While focusing Minimizing Uncertainty at the Pharmaceutical Concentration is important, aggregate OMP expenditure is generally more stable [66].To manage financial uncertainty risks, specific mechanisms like Price/volume pacts, fiscal limits, and mechanisms for reimbursement tied to predetermined budget impact predictions can be established [67,68,69,70-72,73,74,75]. Policymakers should demonstrate sufficient financial uncertainty for such mechanisms to ensure sustainable OMP funding. Care should be taken not to routinely use these mechanisms to undermine OMP value. True uncertainty is related to patient life expectancy and likely treated patient numbers. Managing OMP expenditure growth

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

requires consistent decisions on prices and reimbursement [67].

Table: Principles for Rare Disease Drug Development

Principle	Summary
1	Navigate regulatory framework for rare diseases using Orphan Medicinal Products (OMPs) and expert engagement.
2	Integrate disease-specific expertise in national assessments of OMPs, involving patients, caregivers, and healthcare professionals.
3	Use a multi-criteria approach for value assessment of OMPs, considering rarity, severity, unmet needs, and disease prevalence.
4	Embrace a comprehensive perspective using multi-criteria approaches in OMP value assessments.
5	Acknowledge uncertainty in OMP assessments, considering disease-specific factors and using both qualitative and quantitative evaluation methods.
6	Balance innovation and affordability in OMP regulation, incentivizing research while managing per-patient costs.
7	Establish fair pricing for OMP reimbursement based on added value, considering rarity, disease severity, and development complexity.
8	Navigate the cost-effectiveness conundrum for OMPs, considering adjustments for rarity, severity, and prevalence in economic evaluations.
9	Address limited clinical data challenges for OMP pricing and reimbursement using early access programs, patient registries, and post-authorization safety studies.
10	Manage financial uncertainty in OMP expenditure by implementing mechanisms such as price/volume pacts and reimbursement tied to pre-determined budget impact predictions.

Navigating the Regulatory Landscape of Orphan Drugs in the European Union

Evolution of Regulatory Landscape Orphan Designation within the European Union (EU).This comprehensive review delves into the pivotal changes in EU legislation following the initial enforcement Within the framework of the Orphan Regulation 1999 (Directive 141/2000 Regulation (EC)).

The Parliament of Europe officially ratified The Legislation on Orphan Medicinal Products on 16 December 1999, with its publication Published in the Official Journal of the European Communities on January 22, 2000

The Regulation encompasses several crucial aspects:

Outlines The European Union protocol related to categorizing medications for uncommon diseases.

Establishes prerequisites pertaining to the advancement and commercialization related to rare medicinal products.

Institutes the Committee for Orphan Medicinal Products (COMP).

In a subsequent move, the European Commission, on 27 April 2000, enacted Regulation (EC) No 847/2000, addressing:

The formulation of implementing rules.

The delineation of criteria crucial for effective execution pertaining to the Orphan Regulation.

The current thorough examination provides insights into the structural and procedural facets pertaining to the regulatory landscape governing medications for rare diseases in EU, paving the way for a comprehensive understanding of the legal framework's evolution over time.

Commencing on 28 April 2000, the enactment of this Regulation marked a pivotal moment, prompting sponsors to initiate the submission of orphan classification applications to the European Medicines Agency (EMA). Furthermore, On March 31, 2004, the European Parliament endorsed Directive (EC) No 726/2004, ushering in the establishment of the EMA as the legal entity overseeing the regulated approval and regulation of pharmaceutical items for both for both human and animal health applications.

Key provisions of Directive (EC) No 726/2004 include:

1. Mandating consolidated authorization procedures for all advertising authorizations concerning Medications for rare diseases in the European Union

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

2. Empowering the Committee for Medicinal Products for Human Use (CHMP) to offer Guidelines on compassionate usage programs.
3. Orphan Designation, a prestigious classification bestowed upon drugs intended for rare conditions, requires adherence to specific criteria, ensuring eligibility for incentives such as competition protection upon market entry.

A technical overview pertaining to the regulatory structure for applying for orphan status is detailed in the content table below:

1. Application through the 'IRIS' service
2. Accessing IRIS
3. General principles
4. Compliance process
5. Review of applications

As of 19 September 2018, sponsors are obligated to use the secure online IRIS system of the EMA for submitting applications and coordinating pre- and post-designation activities. IRIS, a secure online portal, streamlines regulatory procedures, offering efficiency and user-friendliness. Sponsors can submit orphan designation requests via two methods:

Direct submission to EMA through the IRIS system, with pre-submission meetings being optional.

Submission through IRIS with advance notice to EMA, although not mandatory, is appreciated.

The application process involves the utilization of specific forms, including a model for the scientific portion of the orphan designation application (sections A to E). Reference documents, guidelines, and recommendations are provided to aid sponsors in the application process. Each application is overseen by two coordinators, one from the Committee for Orphan Medicinal Products (COMP) and one EMA Secretariat Academic Administrator. Requirements for orphan status are thoroughly assessed by EMA, and upon verification, sponsors receive a timetable for the assessment process.

The flowchart below illustrates the sequential steps involved in the orphan designation application process.



(Flowchart: European Union Orphan Drug Designation Application Process)

Economic Efficiency in Orphan Drug Access: A European country Analysis

The evaluation pertaining to medications for rare diseases accessibility within the European Union necessitates a nuanced consideration of the diverse cost and compensation approaches throughout member Nations. Notably, the United Kingdom, Italy, and Spain operate healthcare systems funded through taxation decentralized funds distribution and varying levels of regional autonomy in health technology assessment (HTA) decisions. In contrast, France and Germany employ healthcare funded through Centrally managed social insurance HTA and P&R processes at the national level [76].In France, the Haute Autorité de la Santé (HAS) issues HTA recommendations, influencing subsequent price discussions involving pharmaceutical companies and the Health Department:. The Service Médical Rendu (SMR) rating, defining reimbursement rates, and the Amélioration du Service Médical Rendu (ASMR) rating, indicating incremental therapeutic benefit, play crucial roles. For designated orphan medicinal products (OMPs)

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

with a budget impact below €30 million, full reimbursement is granted, showcasing a distinctive approach to balancing cost considerations [76].

In Germany, the implementation of the Act on the Reform of the Market for Medical Products (AMNOG) in 2011 marked a significant shift in P&R for orphan drugs. While all OMPs were automatically reimbursed before AMNOG, the new legislation introduced HTA requirements and evidentiary standards for additional benefits. Exemption rules, particularly for OMPs with an annual budget impact below €50 million, provide automatic full reimbursement without undergoing extensive HTA evaluation [76].The UK adopts a specialized approach through agencies like the National Institute for Health and Care Excellence (NICE), employing distinct evaluation standards for extremely rare medications. The Advanced Specialized Technologies (AST): program focuses on this category, while the standard Technology Appraisal (TA) program evaluates other OMPs. The Scottish Medicine Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG) incorporate orphan and ultra-orphan modifiers, adding complexity to the evaluation process [76][77].This diversity in approaches underscores the need for a comprehensive understanding of economic efficiency in orphan drug access. Each country's unique system reflects an intricate balance between incentivizing pharmaceutical innovation and managing healthcare expenditure. As policymakers navigate these complexities, acknowledging the necessity of incentivizing OMP development while ensuring sustainable healthcare systems remains paramount [78].

Navigating the Horizon: Anticipating Future Challenges for Orphan Drugs in the European Union

Challenge 1: Comprehensive Approach to Rare Disease Recognition and Management.

Elaboration:

Orphan Disease Designation: In the EU uncommon diseases are frequently termed as orphan conditions. Obtaining orphan drug designation is a crucial step for pharmaceutical companies developing drugs for rare diseases. This designation offers incentives like exclusive market rights, protocol assistance, and reductions in fees However, the process of obtaining orphan designation can be challenging due to stringent criteria and competition.

Control Policy: Once a drug receives orphan designation, companies need to adhere to specific regulations to maintain this status. Ensuring compliance with these policies while conducting research and development is critical. The challenge lies in navigating complex regulatory requirements and adapting to any changes in orphan drug control policies.

Challenge 2: Efficient Strategies for Developing Pre-Clinical and Early-Stage Pharmaceuticals.

Elaboration:

Limited Patient Population: Rare diseases often have a small patient population, making it challenging to conduct robust pre-clinical and early-stage trials. Obtaining statistically significant results can be difficult due to the restricted quantity of eligible individuals seeking medical care, potentially affecting the validity of the research.

Financial Viability: The expenses linked to the development of pharmaceuticals are substantial. With a individual patient population pool, generating sufficient revenue to cover expenses becomes a significant challenge. This financial aspect can hinder investment in research and development for rare disease drugs.

Challenge 3: Identification of Suitable Healthcare Outcome Measures.

Elaboration:

Diversity of Rare Diseases: Each rare disease is unique, and defining appropriate care outcomes can be challenging due to the diversity of these conditions. Identifying meaningful endpoints for clinical trials that reflect the disease's impact on patients' lives is crucial but can be complex.

Patient-Centred Outcomes: Traditional clinical endpoints may not capture the full spectrum of a rare disease's effects on patients. Incorporating patient-centred outcomes, such as quality of life measures, into study designs is essential but requires careful consideration and collaboration with patient advocacy groups.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

Challenge 4: Development and Assessment of Clinical Trial Criteria and Evidence Gathering from Payers.

Elaboration:

Clinical Trial Criteria: Designing clinical trials for rare diseases involves addressing unique challenges, such as patient recruitment difficulties and the absence of established biomarkers. Creating trial criteria that balance scientific rigor with the practical constraints of rare disease research is crucial. Evidence Collection for Payers: Payers, such as health insurance providers, require robust evidence of the effectiveness of a drug and cost-effectiveness. Collecting and presenting this evidence for rare disease drugs can be difficult because of the limited data available and the often unpredictable nature of these diseases.

Market Access: Obtaining reimbursement for rare disease drugs is a significant hurdle. Demonstrating value for money and addressing payer concerns about the limited evidence base are ongoing challenges in ensuring market access for these drugs.

In conclusion, addressing these regulatory challenges requires collaboration between pharmaceutical companies, regulatory authorities, patient advocacy groups, and other stakeholders to develop effective approaches to the successful advancement and commercialization of rare disease drugs in the EU.

Conclusion:

Navigating the regulatory landscape for orphan drugs in the European Union poses multifaceted challenges, encompassing stringent standards for orphan designation, evolving control policies, and the need for efficient strategies in pre-clinical and early-stage development. Identifying suitable healthcare outcome measures, addressing unique clinical trial criteria, and gathering evidence for payers further contribute to the complexity. Overcoming these challenges requires collaborative efforts among pharmaceutical firms, regulatory authorities, and organizations supporting patient interests to ensure the successful development and market access of rare disease drugs.

References

[1] European Commission website: DG Health and Food Safety > Public health > Rare diseases > Policy. Available at: http://ec.europa.eu/health/rare_diseases/policy/index_en.htm

[2] Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. . Available at:http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en. Pdf

[3] Post-orphan Medicinal Product Designation Procedures. Guidance for sponsors 24 January 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/11/WC500196994. Pdf

[4] Commission Regulation (EC) No 847/2000 of 27 April 2000. . Available at: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol1/reg_2000_847/ reg_2000_847_en.pdf.

[5] Franco, P. (2013) Orphan drugs: the regulatory environment. Drug Discov. Today 18, 163–172.

[6]European Union Regulation (EC) No 141/2000 on Orphan Medicinal Products.

[7] Annemans L, et al. Recommendations from the European Working Group for Value Assessment and Funding Processes in rare diseases (ORPH VAL). Orphanet J Rare Dis. 2017;12(1):5.

[8] Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. (2000) Off J Eur Communities. 22.01.2000. L18: 1–5.

[9]European Commission. Regulation (EC) No 141/2000 on orphan medicinal products. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf.

[10]Aymé S, Rodwell C, eds. 2013 report on the state of the art of rare disease activities in Europe. http://www.eucerd.eu/upload/file/Reports/2013ReportStateofArtRDActivities.pdf.

[11].Drummond MF. Challenges in the economic evaluation of orphan drugs. Eurohealth. 2008;14(2):16–7.

[12]Council of the European Union. Council recommendations on rare diseases. http://ec.europa.eu/health/ph_threats/non_com/docs/rare_rec2_en.pdf.

[13] .European Commission. Regulation (EC) No 847/2000. 27 April 2000. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_847/reg_2000_847_en.pdf.

[14] Commission staff working documents on Regulation (EC) No 141/2000.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

http://ec.europa.eu/health/files/orphanmp/doc/orphan_en_06-2006_en.pdf.

[15]European Commission Regulation (EC) No 847/2000. 27 April 2000. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_847/reg_2000_847_en.pdf.

[16]Tambuyzer E. Rare diseases, orphan drugs and their regulation. Nat Rev Drug Discov. 2010;9(12):921–9.

[17]Barham L. Orphan Medicines. Special treatment required? 2020 Health 2012. http://www.2020health.org/2020health/Publications/ publications-2012/ Orphan-Drugs.html.

[18]Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):23–9.

[19]Mavris M, Le Cam Y. The European Medicines Agency and transparency: The rare disease patients' perspective. Regulatory Rapporteur. 2014

[20]Davies JE, Neidle S, Taylor DG. Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care? Br J Cancer. 2012;106(1):14–7.

[21]Clarke JT. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ. 2006;174(2):189–90.

[22]Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.

[23]Barham L. Orphan Medicines. Special treatment required? 2020 Health 2012. http://www.2020health.org/2020health/Publications/ publications-2012/ Orphan-Drugs.html.

[24]Drummond MF. Challenges in the economic evaluation of orphan drugs. Eurohealth. 2008;14(2):16–7.

[25]Schlander M, Beck M. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin. 2009;25(5):1285–93.

[26]Picavet E, Dooms M, Cassiman D, Simoens S. Orphan drugs for rare diseases: grounds for special status. Drug Dev Res. 2012;73:115–9.

[27]Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.

[28]Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74

[29]Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013;16(8):1163–9.

[30]Schlander M, Garattini S, Kolominsky-Rabas P, Nord E, Persson U, Postma M, et al. Incremental cost per Quality adjusted life years gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. Value Health. 2013;16:A324 (abstract CP1).

[31]Platform on Access to Medicines in Europe Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMP). http://ec.europa.eu/enterprise/sectors/healthcare/files /docs/ orphans_framework_en.pdf.

[32]Barham L. Orphan Medicines. Special treatment required? 2020 Health 2012. http://www.2020health.org/2020health/Publications/ publications-2012/ Orphan-Drugs.html.

[33]Simoens S. Market access of orphan drugs and the role of multi-criteria decision making. Orphanet J Rare Dis. 2012;7 Suppl 2:A26.

[34]Irwin J, Peacock S. Multi-Criteria Decision Analysis: An emerging alternative for assessing the value of orphan medicinal products. Regulatory Rapporteur, vol. 12, No 1. 2015.

[35]Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013;16(8):1163–9.

[36]Schey C, Connolly MP. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs- Presented at the European conference on rare diseases and orphan products, 8–10 May 2014, Berlin. http://www.rare-diseases.eu/wp-content/uploads/2013/08/145_t5.pdf. Accessed 13 Feb 2015.

[37]Devlin N, Sussex J. Incorporating multiple criteria in HTA: methods and processes. Office of Health Economics. 2011. https://www.ohe.org/ Gutierrez et al. Orphanet Journal of Rare Diseases (2015) 10:53 Page 8 of 9 publications/incorporating-multiple-criteria-hta-methods-and-processes. Accessed 13 Feb 2015.

[38]Process on Corporate Social Responsibility in the Field of Pharmaceuticals Platform on Access to Medicines in Europe Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMP).

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

http://ec.europa.eu/enterprise/sectors/healthcare/files /docs/ orphans_framework_en.pdf. Accessed 13 Feb 2015.

[39]Rémuzat C, Toumi M, Falissard B. New drug regulations in France: what are the impacts on market access? Part 2 - impacts on market access and impacts for the pharmaceutical industry. J Mark Access Health Policy. 2013;1:20892.

[40]Simoens S. Market access of orphan drugs and the role of multi-criteria decision making. Orphanet J Rare Dis. 2012;7 Suppl 2:A26.

[41]Irwin J, Peacock S. Multi-Criteria Decision Analysis: An emerging alternative for assessing the value of orphan medicinal products. Regulatory Rapporteur, vol. 12, No 1. 2015.

[42]Schey C, Connolly MP. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs- Presented at the European conference on rare diseases and orphan products, 8–10 May 2014, Berlin. http://www.rare-diseases.eu/wp-content/uploads/2013/08/145_t5.pdf. Accessed 13 Feb 2015.

[43]European Commission. Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_ 141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf. Accessed 13 Feb 2015

[44]Butlen-Ducuing F, Riviere F, Aarum S, Llinares-Garcia J. European Medicines Agency support mechanisms fostering orphan drug development. Drug News Perspect. 2010;23(1):71–81.

[45]Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.

[46]Rollet P, Lemoine A, Dunoyer M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet J Rare Dis. 2013;8(1):109. 55. Simoens S, Cassiman D, Dooms M, Picavet E. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012;72(11):1437–43.

[47]Hutchings A, Schey C, Dutton R, Achana F, Antonov K. Estimating the budget impact of orphan drugs in Sweden and France 2013–2020. Orphanet J Rare Dis. 2014;9:22.

[48] Mentzakis E, Stefanowska P, Hurley J. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Health Econ Policy Law. 2011;6(3):405–33.

[49] Burls A, Austin D, Moore D. Commissioning for rare diseases: view from the frontline. BMJ. 2005;331(7523):1019–21.

[50]Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.

[51]Schlander M, Beck M. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin. 2009;25(5):1285–93

[52]McCabe C, Tsuchiya A, Claxton K, Raftery J. Orphan drugs revisited. QJM. 2006;99(5):341–5. discussion 50–1

[53]Hughes D. Rationing of drugs for rare diseases. Pharmacoeconomics. 2006;24(4):315–6

[54]Habl C, Bachner F. EMINET. Initial investigation to assess the feasibility of a coordinated system to access orphan medicines. Vienna, May 2011. Updated Final Report. Commissioned by the European Commission, Directorate-General Enterprise and Industry. 2011. http://ec.europa.eu/enterprise/ sectors/healthcare/files/docs/access_orphans_initialinvest_052011_en.pdf. Accessed 13 Feb 2015.

[55]Chabot I, Rocchi A. Oncology drug health technology assessment recommendations: Canadian versus UK experiences. Clinicoecon Outcomes Res. 2014;6:357–67.

[56]Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74.

[57]Schlander M, Garattini S, Kolominsky-Rabas P, Nord E, Persson U, Postma M, et al. Incremental cost per Quality adjusted life years gained? The need for alternative methods to evaluate medical interventions for ultra rare disorders. Value Health. 2013;16:A324 (abstract CP1).

[58] Farrugia A, O'Mahony B, Cassar J. Health technology assessment and haemophilia. Haemophilia. 2012;18(2):152–7.

[59] Dunoyer M, Rollet P. Value and specificity of rare diseases business model-is the pursuit of this societal priority sustainable? Orphanet J Rare Dis. 2012;7 Suppl 2:A23.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 548-558 | ISSN:2251-6727

[60]Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42

[61] Bélorgey C. Temporary Authorisations for Use (ATU). Agence nationale de sécurité du médicament et des produits de santé. 2001. http://agence-tst. ansm.sante.fr/html/pdf/5/atu_eng.pdf. Accessed 13 Feb 2015.

[62]Agence nationale de sécurité du médicament et des produits de santé. Autorisations Temporaires d'Utilisation. http://ansm.sante.fr/Activites/ Autorisations-Temporaires-d-Utilisation-ATU/Autorisations-Temporaires d-Utilisation/%28offset%29/0. Accessed 13 Feb 2015.

[63]Simoens S, Picavet E, Dooms M, Cassiman D, Morel T. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1–3.

[64]Picavet E, Dooms M, Cassiman D, Simoens S. Orphan drugs for rare diseases: grounds for special status. Drug Dev Res. 2012;73:115–9.

[65]Picavet E, Annemans L, Cleemput I, Cassiman D, Simoens S. Market uptake of orphan drugs–a European analysis. J Clin Pharm Ther. 2012;37(6):664–7

[66] Rollet P, Lemoine A, Dunoyer M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet J Rare Dis. 2013;8(1):109

[67]Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.

[68] Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98(11):829–36.

[69] Simoens S, Cassiman D, Dooms M, Picavet E. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012;72(11):1437–43.

[70] McCabe C, Tsuchiya A, Claxton K, Raftery J. Orphan drugs revisited. QJM. 2006;99(5):341–5. discussion 50–1.

[71] Simoens S, Dooms M. How much is the life of a cancer patient worth? A pharmaco-economic perspective. J Clin Pharm Ther. 2011;36(3):249–56.

[72] Hughes D. Rationing of drugs for rare diseases. Pharmacoeconomics. 2006;24(4):315–6

[73] Owen A, Spinks J, Meehan A, Robb T, Hardy M, Kwasha D, et al. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. J Med Econ. 2008;11(2):235–43

[74]Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy. 2010;8(5):343–50.

[75] Rosenberg-Yunger ZR, Daar AS, Thorsteinsdottir H, Martin DK. Priority setting for orphan drugs: an international comparison. Health Policy. 2011;100(1):25–34

[76]Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in health technology assessment in eight European countries. Rare Dis Orphan Drugs. 2014;1(3):86–97.

[77]Varnava A, Bracchi R, Samuels K, Hughes DA, Routledge PA. New medicines in Wales: the all Wales medicines strategy group (AWMSG) appraisal process and outcomes. PharmacoEconomics. 2018;36(5):613–24.

[78]Rollet P, Lemoine A, Dunoyer M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet J Rare Dis. 2013;8(1):109.